– Action Being Taken Following CE Mark Expiration and Compulsory Recall Request by Agence Nationale de Sécurité du Médicament (ANSM) – DUBLIN, Dec. 19, 2018 /CNW/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that the company has suspended sales of textured breast implants and tissue expanders and is withdrawing any remaining supply in European markets. The withdrawal decision follows a compulsory recall request from Agence Nationale de Sécurité du Médicament (ANSM), the French regulatory authority. The suspension of sales stems from the expiration of the company's CE Mark for these products.

DUBLIN, Nov. 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, and Manisha Narasimhan, PhD, will join the Company as Vice President of Investor Relations and Strategic Initiatives, effective December 10, 2018.

DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Citi Global Healthcare Conference in New York City. The presentation will begin at 11:00 a.m. Eastern Time on Thursday, December 6, 2018.

DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ^® (ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in pediatric patients 3 months to less than 18 years of age.

DUBLIN, Nov. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Credit Suisse 27^th Annual Health Care Conference in Scottsdale, Arizona. The presentation will begin at 1:40 p.m. Mountain Time (3:40 p.m. Eastern Time) on Wednesday, November 14, 2018.

DUBLIN, Oct. 30, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its third quarter 2018 performance. Total third quarter 2018 GAAP net revenues were $3.91 billion, a 3.0 percent decrease from the prior year quarter. THIRD QUARTER 2018 Executive Commentary "Allergan's performance in the third quarter of 2018 highlights the momentum in our business and our focus on execution. We continued to deliver solid results in the third quarter, driven by double-digit growth from many of our key promoted brands, led by BOTOX® Therapeutic and Cosmetic, JUVÉDERM®, and VRAYLAR®," said Brent Saunders, Chairman and CEO of Allergan. "We also maintained momentum in the R&D pipeline with achievements of significant milestones for key programs including cariprazine in bipolar depression, ubrogepant in acute migraine and abicipar in age-related macular degeneration."

"Despite the 3.0 percent decline in net revenue driven primarily by loss of exclusivity on some brands, our core business, representing nearly 90 percent of our total revenues, grew 5.9 percent versus prior year or 7.4 percent excluding foreign exchange. Allergan also maintained strong operating margins and grew non-GAAP performance net income per share. Our business continues to generate robust cash flows, and we are maintaining a disciplined approach to capital allocation – with a strong balance sheet, strategic growth investments and capital returns to our shareholders," added Saunders. "With this strong momentum in the business and based on our revised expectations for RESTASIS®, we increased our full-year 2018 guidance for net revenue and non-GAAP performance net income per share."

"I am proud of what our team has accomplished this year and excited about our potential to create more value for patients, employees and shareholders for many years to come."

DUBLIN, Oct. 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the fourth quarter of 2018. The dividend will be paid on December 14, 2018 to shareholders of record at the close of business on November 13, 2018.

DUBLIN, Oct. 23, 2018 /PRNewswire/ -- Actress for the Emmy- and Golden Globe-winning series "Sex and the City," philanthropist and mom, Kristin Davis, is partnering with CoolSculpting^® – the FDA-cleared non-surgical, clinically proven treatment that eliminates stubborn fat using a patented cooling technology, owned by Allergan plc (NYSE: AGN) – as the partner of the "Denim Denial" consumer program. Denim Denial recognizes that every woman has a pair of jeans on the top shelf of her closet or tucked away in a bottom drawer but is holding on to them with the goal of fitting into them again someday when she frees herself of that last bit of stubborn fat. As the face of the program, Davis joins CoolSculpting^® in its mission to inspire women across the country to learn more about personalized body contouring to achieve their own desired results, including fitting back into their favorite pair of denim.

WACO, Texas, Oct. 22, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that The Allergan Foundation has awarded a $125,000 grant to support "Heroes MAKE America," a career program for veteran candidates in the United States Military. The sponsorship was announced as part of a visit by "Heroes MAKE America" students to Allergan's Waco manufacturing site. "Heroes MAKE America" is a National Association of Manufacturers' (NAM) Manufacturing Institute program that offers transitioning service members advanced training in manufacturing skills, industry certifications and college credits, as well as providing them with the opportunity to connect with prospective employers.